Newamsterdam Pharma Company N V 's ability to collect accounts receivable sequentially worsen to 4.11, indicating more challenging environment then in the fourth quarter 2025, but still, it is a far cry from any concerns. Newamsterdam Pharma N V 's Accounts Receivable average collection period in the Mar 31 2026 quarter, has increased to 89 days, from 62 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 489 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 3230, from overall ranking in the fourth quarter 2025 at 3305.

What is Receivable Turnover Ratio?
What is Newamsterdam Pharma Company N V Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NAMS Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	455.83 %	287.01 %	136.88 %	54.12 %	-63.81 %
Y / Y Revenue Change	2.08 %	-99.75 %	-98.8 %	740.06 %	112.56 %
Receivable Turnover Ratio (TTM)	4.11	5.85	13.58	31.51	27.05
NAMS's Total Ranking	# 3230	# 3305	# 2052	# 2906	# 3082
Accounts Receivable average collection period days	89	62	27	12	13
Seq. Receivable Change	18.48 %	73.51 %	18.55 %	128.09 %	-17.51 %
Seq. Revenue Change	9400 %	-90.8 %	-98.18 %	542.88 %	-76.68 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 169
Healthcare Sector	# 490
Overall Market	# 3230

Receivable Turnover Ratio Statistics
High	Average	Low
0.09	0.06	0.03
(Jun 30 2025)

NAMS Company Profile • Back to NAMS Efficiency Comparisons • Compare NAMS Receivables Turnover Ratio to its Competitors

Financial Statements
Newamsterdam Pharma N V 's Accounts Receivable	$ 8 Millions	Visit NAMS's Balance sheet
Newamsterdam Pharma N V 's Sales TTM	$ 23 Millions	Visit NAMS's Income Statement
Sources of NAMS's Revenues		Visit NAMS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NAMS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NAMS's Growth Rates	NAMS's Roa	NAMS's Inventory Turnover Ratio	NAMS's Dividend Comparisons
NAMS's Profitability Ratios	NAMS's Roi	NAMS's Asset Turnover Ratio	NAMS's Dividend Growth
NAMS's Valuation Ratios	NAMS's Roe	NAMS's Financial Strength Ratios	NAMS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Pacs Group Inc	7.71	$ 5,432.276 Millions	$ 704.948 Millions
Acadia Healthcare Company Inc	7.70	$ 3,371.066 Millions	$ 437.934 Millions
Plus Therapeutics Inc	7.70	$ 5.182 Millions	$ 0.673 Millions
Quest Diagnostics Inc	7.69	$ 11,278.000 Millions	$ 1,467.500 Millions
Uniqure N v	7.68	$ 18.093 Millions	$ 2.356 Millions
Natera Inc	7.64	$ 2,500.927 Millions	$ 327.432 Millions
Cannapharmarx Inc	7.57	$ 1.654 Millions	$ 0.219 Millions
Foxo Technologies Inc	7.56	$ 27.325 Millions	$ 3.615 Millions
Omada Health Inc	7.55	$ 281.916 Millions	$ 37.326 Millions
Tela Bio Inc	7.55	$ 80.349 Millions	$ 10.643 Millions
Novocure Limited	7.54	$ 674.414 Millions	$ 89.464 Millions
Intuitive Surgical Inc	7.49	$ 10,582.100 Millions	$ 1,412.950 Millions
Cue Biopharma Inc	7.48	$ 32.731 Millions	$ 4.378 Millions
Maravai Lifesciences Holdings Inc	7.46	$ 203.841 Millions	$ 27.333 Millions
Travere Therapeutics Inc	7.42	$ 536.195 Millions	$ 72.285 Millions
Lemaitre Vascular Inc	7.42	$ 256.515 Millions	$ 34.583 Millions
Twist Bioscience Corporation	7.41	$ 409.479 Millions	$ 55.272 Millions
Quidelortho Corp	7.39	$ 2,657.200 Millions	$ 359.600 Millions
Koru Medical Systems Inc	7.38	$ 43.257 Millions	$ 5.863 Millions
Si bone inc	7.38	$ 206.128 Millions	$ 27.945 Millions
Avita Medical Inc	7.36	$ 72.347 Millions	$ 9.832 Millions
Nephros Inc	7.32	$ 19.464 Millions	$ 2.659 Millions
Aurinia Pharmaceuticals Inc	7.30	$ 298.295 Millions	$ 40.837 Millions
Rhythm Pharmaceuticals Inc	7.27	$ 217.165 Millions	$ 29.857 Millions
Castle Biosciences Inc	7.25	$ 339.920 Millions	$ 46.860 Millions
10x Genomics Inc	7.20	$ 637.614 Millions	$ 88.572 Millions
Star Equity Holdings Inc	7.17	$ 209.296 Millions	$ 29.202 Millions
Angiodynamics Inc	7.16	$ 311.277 Millions	$ 43.494 Millions
Universal Health Services Inc	7.15	$ 18,292.509 Millions	$ 2,558.777 Millions
Verastem Inc	7.14	$ 49.585 Millions	$ 6.941 Millions

Date modified: 2026-07-07T12:17:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.